Related Experiment Video
Updated: Mar 11, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression
Swathi V Iyer1, Atul Ranjan1, Harold K Elias2
1Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Wahl East 2005, Kansas City, Kansas 66160, USA.
Abstract:
The ability of cancer cells to survive and grow in anchorage- and serum-independent conditions is well correlated with their aggressiveness. Here, using a human whole-genome shRNA library, we identify TMIGD3 isoform1 (i1) as a factor that suppresses this ability in osteosarcoma (OS) cells, mainly by inhibiting NF-κB activity. Knockdown of TMIGD3 increases proliferation, tumour formation and metastasis of OS cells. Overexpression of TMIGD3 isoform1 (i1), but not isoform3 (i3) which shares a common C-terminal region, suppresses these malignant properties. Adenosine A3 receptor (A3AR) having an identical N-terminal region shows similar biological profiles to TMIGD3 i1. Protein expression of TMIGD3 and A3AR is lower in human OS tissues than normal tissues. Mechanistically, TMIGD3 i1 and A3AR commonly inhibit the PKA-Akt-NF-κB axis. However, TMIGD3 i1 only partially rescues phenotypes induced by A3AR knockdown, suggesting the presence of distinct pathways. Our findings reveal an unappreciated role for TMIGD3 i1 as a suppressor of NF-κB activity and OS progression.
Insights
TMIGD3 isoform1 suppresses osteosarcoma (OS) aggressiveness by inhibiting NF-κB. Lower TMIGD3 and A3AR expression in OS tissues correlates with increased tumor progression and metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Cancer cell survival and growth in anchorage- and serum-independent conditions correlate with aggressiveness.
- Osteosarcoma (OS) is a challenging bone cancer with significant metastatic potential.
Purpose of the Study:
- To identify factors suppressing anchorage- and serum-independent growth in osteosarcoma cells.
- To elucidate the role of TMIGD3 isoform1 in osteosarcoma progression and NF-κB signaling.
Main Methods:
- Utilized a human whole-genome shRNA library to screen for suppressors of malignant phenotypes.
- Investigated the effects of TMIGD3 isoform1 and isoform3 on osteosarcoma cell proliferation, tumor formation, and metastasis.
- Analyzed the involvement of the PKA-Akt-NF-κB signaling axis.
Main Results:
- TMIGD3 isoform1 (i1) was identified as a suppressor of aggressive phenotypes in osteosarcoma cells.
- Knockdown of TMIGD3 increased proliferation, tumor formation, and metastasis, while overexpression suppressed these properties.
- TMIGD3 i1 and Adenosine A3 receptor (A3AR) share similar inhibitory effects on the PKA-Akt-NF-κB axis, with lower expression in OS tissues.
- TMIGD3 i1 partially rescued A3AR knockdown phenotypes, indicating distinct yet overlapping pathways.
Conclusions:
- TMIGD3 isoform1 acts as a novel suppressor of NF-κB activity and osteosarcoma progression.
- TMIGD3 i1 and A3AR represent potential therapeutic targets for osteosarcoma treatment.
- Understanding the distinct pathways regulated by TMIGD3 i1 is crucial for developing targeted therapies.
Related Concept Videos
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

